2026-06-27T12:32:13Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/971482025-03-18T12:10:28Zcom_20.500.14352_14col_20.500.14352_15

Benchekroun, Mohamed Romero Hernández, Alejandro Egea, Javier León Martínez, Rafael Michalska Dziama, Patrycja Buendía, Izaskun Jimeno, María Luisa Jun, Daniel Janockova, Jana Sepsova, Vendula Soukup, Ondrej Bautista-Aguilera, Oscar Refouvelet, Bernard Ouari, Olivier Marco Contelles, José Luis Ismaili, Lhassane 2024-01-31T12:44:37Z 2024-01-31T12:44:37Z 2016 Benchekroun, Mohamed, et al. «The Antioxidant Additive Approach for Alzheimer’s Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators». Journal of Medicinal Chemistry, vol. 59, n.o 21, noviembre de 2016, pp. 9967-73. https://doi.org/10.1021/acs.jmedchem.6b01178. 0022-2623 10.1021/acs.jmedchem.6b01178 https://hdl.handle.net/20.500.14352/97148 https://doi.org/10.1021/acs.jmedchem.6b01178 Novel multifunctional tacrines for Alzheimer’s disease were obtained by Ugi-reaction between ferulic (or lipoic acid), a melatonin-like isocyanide, formaldehyde, and tacrine derivatives, according to the antioxidant additive approach in order to modulate the oxidative stress as therapeutic strategy. Compound 5c has been identified as a promising permeable agent showing excellent antioxidant properties, strong cholinesterase inhibitory activity, less hepatotoxicity than tacrine, and the best neuroprotective capacity, being able to significantly activate the Nrf2 transcriptional pathway. eng restricted access The Antioxidant Additive Approach for Alzheimer’s Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators journal article